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Objective. Prevalence of depressive symptoms in the post-myocardial infarction (MI) 
period varies from 8 to 30%. Cerebral damage after MI, caused by transient ischemia, 
an inflammatory response or both, may contribute to development of post-MI depression. 
S100B is an established protein marker of cerebral damage. In a pilot study, the authors 
assessed whether S100B serum levels are: (1) increased during the week after MI, and (2) 
related to depressive symptoms during index hospital admission and the year following MI.
Methods. This pilot study is a substudy of the Myocardial Infarction and Depression 
Intervention Trial (MIND-IT). In 48 patients, serum levels of S100B were available at 1, 
2, 3, 4 and 8 days following MI. Subsequently, in 27 patients, depressive symptoms were 
measured at 0, 3, 6, 9 and 12 months following MI with the Beck Depression Inventory 
(BDI). In 21 of the initial 48 patients, BDI data were lacking due to refusals to fill out BDI 
forms or missing data. 
Results. Significant and transient increases in serum S100B were observed in 81.3% of 
the 48 patients: 37.5% reached S100B serum levels comparable to serum levels found in 
acute brain injury (> 0.20 µg/l) and 43.8% reached mildly elevated S100B serum levels 
comparable to serum levels found in depressive disorder (0.10–0.20 µg/l). In 18.7%, no 
S100B was detected in serum. Using nonparametric Spearman rank correlation tests, a 
trend towards an association was found between serum S100B and depressive symptoms 
during the post-MI year ( r values between 0.16 and 0.53) in 27 patients who completed 
both the S100B serum study and the BDI study. 
Conclusion. Transiently elevated levels of S100B are suggestive of minor acute cerebral
damage in the first days following MI and associated with depressive symptoms in the 
year following MI. Cerebral damage could be an important mechanism in the pathogen-
esis in a subtype of post-MI depression.
aBSTRaCT
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Depressive symptoms following myocardial infarction (MI) have been associated with 
arrhythmic events and an increased risk of cardiac death up to 5 years after MI [1]. In a 
recent meta-analysis, the odds ratios for allcause mortality and cardiac mortality were 
estimated to be 2.38 and 2.59, respectively [2]. The prevalence of depressive symptoms 
varies from 8 to 30% depending on the assessment method [3]. Cerebral damage, caused 
by transient ischemia, an inflammatory response or both, may contribute to induction of 
post-MI depression. Proinflammatory cytokines, including TNF-α, affect blood-brain bar-
rier (BBB) integrity [4], and in experimental animal studies MI was associated with brain 
damage, most likely through immune-mediated processes [5]. Brain damage might also 
occur in human MI patients as a result of regular TNF-α release after MI [6]. Neuroimag-
ing supports the association between subtle cerebral damage and depressive symptoms, 
since in clinically depressed but physically healthy patients cerebral white matter lesions 
(WML) are found [7]. WML in the elderly are associated with a 3- to 6-times higher risk of 
depressive symptoms compared to patients without WML [8]. Moreover, it was shown that 
MI and WML are related to each other [9]. Certain proteins in blood circulation may serve 
as markers of central nervous system (CNS) injury. Such an established marker is S100B, 
a calcium-binding protein of the S100 family that comprises 21 members. It is present 
in high concentrations in astroglial and oligodendroglial cells in the CNS, and is normally 
not detected in peripheral blood. Increased serum S100B levels may indicate glial 
alterations, either due to brain damage or functional secretion of S100B by astrocytes. 
Disruption of the BBB is mandatory to allow for cerebral efflux [10]. extracellular S100B 
exerts a dual effect on neurons depending on its concentration, i.e. a pro-survival effect 
on neurons and stimulation of neurite outgrowth at nanomolar doses and a toxic effect at 
micromolar doses [11,12] Circulating S100B has a biological half-life of 25 min [13]. Follow-
ing acute structural cerebral damage, S100B leaks into the bloodstream either directly 
from damaged tissue or indirectly via extra-cellular space. S100B efflux due to acute 
significant cerebral damage leads to a characteristic curve of S100B serum levels. Usu-
ally, the highest serum levels of S100B are observed 2–4 days after acute brain damage 
and normalize thereafter within 1–3 weeks [14]. S100B serum levels reflect S100B Cerebro 
Spinal Fluid levels [15]. After acute cerebral injury, serum S100B levels > 0.30 µg/l at 48 h 
have predictive value for long-term anxiety [16] , serum S100B > 0.50 µg/l for persist-
ing neuronal damage [17] and serum S100B > 0.70 µg/l for death [18]. In several (neuro) 
psychiatric disorders, e.g. melancholic depression, elevation of S100B in serum is rather 
subtle (0.10–0.20 µg/l) and over time becomes more pronounced [12, 19–21]. S100B can 
also be found in serum after exercise with high cardiac output when activities included 
repetitive jarring movements or contact with the head (running), but not after exercise on 
a stationary bicycle, probably reflecting astroglial and/or BBB reaction in the first group 
[10]. However, in certain circumstances S100B is released from extra-cerebral tissues, e.g. 
after trauma, melanoma and cardiac surgery [22–24]. Therefore, it could be argued that 
serum S100B is not solely a marker for cerebral damage, but also a marker of cardiac 
damage. Fortunately, due to the short half-life of S100B and human renal clearance of 
2 h, release of S100B from different damaged tissues leads to different time curves of 
the (peak) appearance of S100B in serum [14, 25]. This makes it possible to discriminate 
between different tissue origins of S100B, as was done in studies on cardiac surgery 
with cardiopulmonary bypass procedure (CPB) where both cerebral and cardiac sources 
of serum S100B were established [25]. During CPB, S100B was found in special reservoirs 
for cardiac surgical wound blood not contaminated by cerebral blood flow [26] and S100B 
serum levels measured immediately after cardiac surgery did correlate with measures of 
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cardiac injury and not with neuropsychological outcome, which points to a cardiac source 
of S100B [27]. However, several other studies found a strong positive correlation between 
increased S100B serum levels and cerebral dysfunction after cardiac surgery, pointing to 
a cerebral origin of S100B in CPB [28–30]. The combination of these results suggested that 
in CPB two different pathophysiological mechanisms are responsible for S100B release in 
serum. Therefore, later on, the clinical significance of early and late release of S100B af-
ter CPB were analyzed separately [28]. Timing of its appearance in the circulation indicated 
that serum S100B has an early peak (immediately at the end of surgery) associated with 
cardiac damage measured by creatine kinase (CK) [27] or troponin I [25], and a late peak 
(5–48 h after surgery) associated with neurological dysfunction after cardiac surgery [25, 
28]. As far as we know, data on the relation between S100B and MI are lacking. To validate 
the hypothesis that cerebral damage may occur after MI and may contribute to induction 
of post-MI depression we investigated: (1) whether S100B serum levels are increased dur-
ing the week after MI, (2) the timing of its appearance in serum to discriminate between 
cardiac and cerebral sources, and (3) whether S100B serum levels in the first week after MI 
are related to depressive symptoms during hospital admission and the year following MI.
Study Population
Data were derived from the Myocardial Infarction and Depression Intervention Trial (MIND-
IT), a multi-center randomized controlled study on the effects of antidepressant therapy 
for post-MI depression on cardiovascular prognosis. Inclusion and exclusion criteria have 
been described previously [31]. In brief, we recruited consecutive patients (September 
1999–November 2002) hospitalized for acute MI in 10 hospitals across the Netherlands. 
Patients were enrolled if they met WHO MONICA criteria for definite MI. The patients for 
the S100B sub-study were all inpatients at the Coronary Care Unit of Medical Centre, 
Leeuwarden, the Netherlands, 1 of the 10 participating hospitals of the MIND-IT study. 
exclusion criteria were: occurrence of MI while the patient was hospitalized for another 
reason, inability to participate in study procedures, a disease likely to influence short-
term survival, receiving psychiatric treatment for depression already and participation in 
another clinical trial.
Procedures
Fifty-three consecutive patients (35 men and 18 women; age range 47–76 years) entered 
the S100B study. After written informed consent for participation in the S100B study, 
blood was collected by means of a venous puncture 5 times during the week after MI. 
Blood samples (6 ml) for S100B assays were taken on the day of admittance as soon as 
diagnosis of MI was given, before the start of thrombolytic therapy. Time interval between 
time of admittance for MI and the first S100B measurement varied between 1 and 3 h 
(mean 1.8 h). According to changes in the electrocardiograph, reperfusion was obtained 
2–12 h after admittance for MI (mean 5 h). Information was obtained from clinical re-
cords by the participating cardiologist. Subsequently, on days 2, 3, 4 and 8, a fixed sched-
ule was used and all venous punctures were performed at 8 a.m. After blood for S100B 
determination was collected, patients were asked to participate in the MIND-IT study. As 
part of this study, patients with MI were screened for depressive symptoms during initial 
hospitalization (0 months) and 3, 6, 9 and 12 months after MI with the 21-item Beck 
Depression Inventory (BDI) questionnaire, an established method for screening depressive 
METHOdS
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disorders in cardiac patients [32]. Demographic and medical information were obtained 
from the patients’ medical records ( table 1).
Variable %
Male sex 58.3 (28)
Age >60 years 56.3 (27)
Anterior MI 33.3 (16)
Cardiac history (MI, PCI, CABG) 12.5 (6)
CK-MB (mean 8 SD), U/l 197± 164
Peak CK (mean 8 SD), U/l 2,080±1,650
LVeF <45% 20.9 (10)
Medication at hospital admittance
   Acenocoumarol 2.1 (1)
   b-Blockers 14.6 (7)
   Diuretics 12.5 (6)
   Calcium antagonists 8.3 (4)
   Statins 12.5 (6)
   ACe inhibitors 8.3 (4)
Medication during acute treatment phase
    Thrombolysis 100.0 (48)
    Nitrates 100.0 (48)
    Heparin 100.0 (48)
    Ascal 100.0 (48)
Medication at day 8
    Nitrates 20.8 (10)
    Ascal 83.3 (40)
    Acenocoumarol 18.8 (9)
    b-Blockers 85.4 (41)
    Diuretics 22.9 (11)
    Calcium antagonists 35.4 (17)
    Statins 77.1 (37)
   ACe inhibitors 27.1 (13)
Values are percentages with the numbers of subjects given in parentheses, unless otherwise indicated. PCI = 
Percutaneous coronary intervention; CABG = coronary artery bypass graft surgery; LVeF = left ventricular ejection 
fraction; ACe = angiotensin-converting enzyme.
From the 53 patients participating in the S100B study, 30 agreed to continue in the MIND-
IT study and fill in BDI forms, whereas 23 refused. After BDI forms were completed, miss-
ing data were calculated for S100B only (n = 3), BDI only (n = 1) and both S100B and BDI 
(n = 2). Finally, complete data on S100B were available for 48 patients. Additionally, for 
27 of these 48 patients, complete BDI data were available (Fig.1). The investigation was 
carried out in accordance with the latest version of the Declaration of Helsinki and the 
local ethical committees approved the design of the MIND-IT study. A separate informed 
consent was required by the local ethical committee of the Medical Centre of Leeuwarden 
for the collection of the S100B data. All participants were fully informed, and gave written 
informed consent.
Table 1. Baseline and treatment characteristics  
for S100B.
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CK/CK-MB was used as a marker of the presence of MI, not for infarct size, as all patients 
received thrombolytic therapy after admission [33]. Left ventricular ejection fraction (LVeF) 
was used as a more reliable marker of infarct size. Details on the measurement of CK and 
LVeF were described previously [31,34].
Biochemistry
Heparinized serum samples were centrifuged within 2 h at 2,300 g ; aliquots were taken 
and frozen at –20 ° C until analysis. S100B was determined with an immunofluorometric 
sandwich assay using a monoclonal anti-S100B chain antibody (LIA-mat R Sangtec Kit 
and Magic Little Analyzer 2, version 4.0; Sangtec, Bromma, Sweden). The Sangtec 100 
LIA immunol-uminometric assay uses tubes coated with 2 monoclonal antibodies as solid 
phase, and a monoclonal antibody for detection. The assay measures concentrations of 
S100B protein over the range of 0.02–20 µg/l. Measurements were performed according 
to the instructions of the manufacturer. Details about linearity, a description of the ana-
lytical technique, the accuracy and precision, and limit of quantification of the kit were 
described earlier [35] . The assay’s threshold for detecting S100B is 0.02 µg/l. To minimize 
inter-assay variations, S100B was determined after all samples were collected.
Statistical Analysis
No sample size calculation was performed due to the exploratory nature of the trial. 
S100B data are expressed as medians and interquartile ranges, which are less affected 
by outliers in a small sample than means and standard deviations. Missing S100B 
data (6.7%) and missing data on the BDI (4.4%) were estimated by means of 2-way 
imputation [36]. The method was only used for patients with 2 or fewer missing values. As 
a consequence, 5 patients were excluded from further analyses on S100B, and 3 patients 
were excluded from analyses involving the BDI (Fig.1). Brain damage was expressed as 
both S100B peak value between day 2 and 4, and S100B area under the curve (AUC). AUC 
was calculated for each participant by integrating simple linear functions, which were 
set up using S100B at days 1, 2, 3, 4 and 8. The course of S100B during the first week 
after MI was evaluated with non-parametric pairwise comparisons between S100B at day 
1,S100B peak value (days 2–4) and S100B at day 8 (Wilcoxon signed rank test). The rela-
tionships of S100B peak values and S100B AUC with BDI scores and LVeF, respectively, as 
Figure 1. Flow chart of patients in the S100B 
and subsequently the MIND-IT study. Missing 
data: S100B only (n = 3), BDI only (n = 1) and 
both S100B and BDI (n = 2).
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a measure of MI severity, were evaluated with non-parametric Spearman rank correlation 
tests (r). Given the small sample size, a was set at 0.10 to increase statistical power.
With regard to the peak levels of serum S100B, 3 subcategories of patients were made in 
order to allow comparison (especially in the low range) with (neuro) psychiatric diseases 
in which elevated S100B concentrations are known to occur and are related to clinical 
symptoms. The first group was defined as having no S100B serum levels above 0.10 µg/l, 
which is comparable with healthy controls [37]. The second group was defined according to 
mildly elevated S100B levels between 0.10 and 0.20 µg/l, comparable with levels found in 
melancholic depression [21]. The third group was defined according to serum S100B levels 
> 0.20 µg/l measured in various degrees of acute neurological pathology ranging from 
minor traumatic head injury [38] to stroke with unfavorable outcomes [10, 14, 17, 23, 28, 30, 38].
Subjects (n = 30) who filled out a BDI did not differ from those who refused (n = 23) with 
respect to age, gender, co-morbidity, renal function, MI severity (LVeF) or S100B values.
Serum S100B Levels and Time Course
Non-parametric pairwise comparisons revealed significant differences for the sample as 
a whole between S100B at day 1 and S100B peak value (Z = –4.01; p< 0.001).
No significant difference was found between S100B at day 1 and S100B at day 8 (Z = 
–1.14; p = 0.25). 
Depressive symptoms S100B peak value S100B AUC
First week after MI 0.07 0.16
3-month follow-up 0.47** 0.34*
6-month follow-up 0.30 0.23
9-month follow-up 0.53*** 0.34*
12-month follow-up 0.36* 0.16
* p < 0.10; ** p < 0.05; *** p < 0.01.
RESUlTS
Figure 2. Time course of median S100B serum 
levels of the whole sample following MI (n= 48). 
The error bars represent the interquartile range.
Table 2. Spearman’s r correlation coefficients 
for S100B (peak value and AUC) and depressive 
symptoms at baseline and follow up.
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Figure 2 shows the temporal pattern of the median S100B levels and in- terquartile range 
of the whole group (n = 48). Nine patients (18.7%) had no serum S100B levels above 
0.10 µg/l. The second group of 21 patients (43.8%) had mildly elevated serum S100B 
levels between 0.10 and 0.20 µg/l, comparable with levels found in melancholic depres-
sion [21]. In the third group of 18 patients (37.5%), serum S100B levels were significantly 
elevated and reached levels > 0.20 µg/l as measured in acute neurological pathology. 
Five of these reached values analogous to values seen in the range of severe cerebral 
pathology, e.g. stroke (> 0.35 µg/l; Fig. 3).
Serum S100B and Infarct Size
S100B peak value (r = –0.14; P= 0.49) and S100B AUC (r = 0.03; P = 0.90) were not 
associated with LVeF (n =48).
Serum S100B and Depressive Symptoms
Depressive symptoms assessed at initial hospitalization were not related to serum S100B 
peak value and serum S100B AUC (Fig. 3; n = 27). However, serum S100B peak values 
and serum S100B AUC were both associated with the BDI score of depressive symptoms 
at follow-up (Fig. 3). As shown in table 2, a consistent pattern of significant correlations 
and trends was found for depressive symptoms assessed at 3, 6, 9 and 12 months after 
MI (n = 27).
Figure 3: Scatter plots: relation between serum 
S100B peak value (µg/l) and BDI score.
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This pilot study is the first to report that S100B serum levels may be increased in the first 
week after MI in a time and peak pattern comparable with serum S100B release after 
acute cerebral damage (Fig. 2). Moreover, a trend towards an association was found 
between serum S100B levels and depressive symptoms during the first year after MI, 
especially at the later measurement points 3–12 months after MI (table 2). S100B serum 
levels were not associated with infarct size as derived from LVeF. These data indicate 
that cerebral damage may play a role in the development of post-MI depression. Although 
we measured plasma CK/CK-MB, it was not used as a marker of infarct size as early 
thrombolytic therapy is a confounder in this situation [33]. Therefore, we preferred LVeF as 
a marker for infarct size.
The results are consistent with previous studies on the association between the late 
increase in S100B serum levels and cognitive/neurological dysfunction after CPB [25,28]. In 
late release, defined as the first 5–48 h after CPB, S100B serum contamination from car-
diac sources is presumed to be insignificant [24, 28]. Our study results are also in line with 
the observation that heightened S100B serum levels (>0.30 µg/l) 48 h after CPB might 
predict long-term (3–6 years) anxiety [16] demonstrating that a single cardiac event might 
result in long lasting psychiatric symptoms. In light of these studies it is not surprising 
that another single cardiac event as MI may result in long-lasting depressive symptoms.
As the relation between S100B serum levels and MI is unknown, the question to be con-
sidered here is whether the S100B serum levels after MI have a cerebral, cardiac
or mixed origin. Several arguments favor a predominantly cerebral origin of the S100B 
serum levels we found in this pilot study. The isolated ischemic rat heart releases S100B, 
but only for a maximum of 60 min after myocardial ischemia [39]. As yet no data are avail-
able in man.
Considering the short biological half-life of S100B of 25 min and human renal clear-
ance of 2 h [13] the supposed early but transient cardiac release of S100B due to MI will 
probably only last from some minutes to an hour. This rise will probably remain unnoticed 
when examining serum samples taken at least several hours following MI, as was the 
case in this study. As the average time between hospital admittance for MI and the first 
serum S100B measurement point was 1.8 h, and time between admittance for MI and 
reperfusion 5 h, we cannot completely rule out that cardiac S100B added to the amount of 
serum S100B, especially in the serum S100B measurements on day 1. For the measure-
ments of serum S100B on days 2–8 this is highly unlikely, considering the half-life of 25 
min. Moreover, we did not find any association between LVeF and S100B serum levels, 
which also points to an extracardiac origin of S100B.
In addition, the cerebral origin of serum S100B is strongly backed up by the time course, 
with a peak of median S100B serum levels on days 2–3 after MI (Fig. 2). The pattern is 
the same as seen after primary acute cerebral injury [14] and also corresponds with the 
time pattern of late-release serum S100B associated with cerebral damage after CPB [25, 
28]. The observed S100B serum levels (Fig. 3) are also comparable to S100B levels found 
in various neurological and psychiatric study populations. In order to estimate the clinical 
significance of the measured S100B serum levels, we divided our study population into 
3 subgroups. This made comparison possible with previous study populations in which a 
relation was established between serum S100B and the clinical disease examined. The 
first group (18.7%) had no S100B elevation at all, therefore the conclusion that MI does 
not automatically lead to late (5–48 h) release of serum S100B is justified. The second 
group (43.8%) was defined according to S100B levels found in depressive disorder 
(0.10–0.20 µg/l) [21]. The third group (37.5%) had levels >0.20 µg/l that can be found in 
dISCUSSION
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various forms of cerebral damage ranging from minor traumatic head injury to stroke [10, 
14, 17, 23, 28, 30, 38]. This last comparison adds to the preliminary conclusion that the serum 
S100B levels we found might have clinical relevance.
The variation in S100B levels between the 3 groups is probably due to individual variation 
in cerebral vulnerability for changes after MI, which is consistent with the observation 
that patients with a previous history of stroke or transient ischemic attack had higher 
levels of S100B directly after CPB than those who did not [28]. We presume that the inci-
dental high serum S100B levels > 0.35 µg/l in the range of serious neurological damage 
[10, 30] may point to small non-progressive brain lesions, formed shortly before blood was 
collected as none of the patients experienced physical neurological symptoms. Consistent 
with the latter is that in a serum S100B serial measurement study of head trauma, values 
of 0.9 µg/l were measured with a rapid decline to 0.2–0.4 µg/l during the first 12 h after 
the trauma [40]. None of the patients in our study had persistently high serum S100B 
values. The clinical relevance of glial protein S100B in depressive disorder has not yet 
been established. Histopathological post-mortem studies showed consistent reductions in 
glial cell density in prefrontal brain regions of depressive patients [41]. A relation between 
elevated serum S100B levels and melancholic major depression (a subtype of depressive 
disorder) was established in physically healthy patients [19]. It was replicated for other but 
not all types of depressive disorder [19, 21]. In case of association between depressive disor-
der and S100B serum levels, the levels were consistently between 0.05 and 0.2 µg/l [21].
Antidepressant drugs influence secretion of S100B by astrocytes via the serotonergic 
system [42]. S100B may induce neurogenesis [43] that is required for behavioral effects of 
antidepressants [44]. Four treatment studies showed that S100B decreases after success-
ful antidepressant treatment [20, 21, 45, 46]. Patients with increased S100B levels had a better 
therapeutic response than those with normal S100B levels [46]. However, the effect sizes
differ [21], and this may have its origin in the fact that depressive disorder is a hetero-
geneous group of psychiatric disorders with different neurobiological and psychological 
characteristics. It is a spectrum disorder with at one-end characteristic predominant 
psychological symptoms, possibly reflecting only a ‘psychological’ reaction to stressful 
circumstances including a life-threatening disease; the other end is characterized by se-
vere somatic symptoms combined with a typical cognitive profile, and related to somatic 
diseases such as brain damage, MI and severe LV dysfunction in which it is difficult to 
assess whether the depression is a ‘biological’ consequence of the illness itself or not [8, 47].
The MIND-IT study provided evidence for the same heterogeneity in post-MI depression 
[47] . Moreover, it was found that a significant number of patients were depressed before 
MI, and impaired cardiovascular prognosis and heightened mortality were found only 
in patients with incident post-MI depression. Incident post-MI depression might be a 
depressive subtype that is a pathophysiological consequence of cardiovascular illness 
itself [48] .
The association of elevated S100B levels in the first week after MI with depressive 
symptoms at 3- to 12-month follow-up indicates that de novo cerebral damage may 
contribute to the development of post-MI depression. This is also indicative of a specific 
(biological) subtype of post-MI depression, and in line with earlier reports on cardiac 
events and induction of psychopathology [16]. Although there seems to be a connection, the 
small number of patients causes a statistical weakness of association between S100B 
and depressive symptoms.
Large-scale studies are necessary to gather more in-depth insight into the connection 
between S100B levels and depressive symptoms.
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As different subtypes of post-MI depression have a different response to treatment 
and non-response is associated with more cardiac events [48], it is important to obtain 
knowledge about possible mechanisms in the association between depressive symptoms 
and MI in the several subtypes of post-MI depression in order to develop prophylactic and 
therapeutic regimens, both in terms of quality of life and prognosis.
Given the dual (survival and toxic) effect on neurons and its wide variety of intra- and 
extra-cellular functions, it remains to be proven if the increase in S100B serum concen-
tration in our study is due to substantial destruction of CNS tissue or to an active release 
of S100B from intact astrocytes attempting to repair neuronal damage.
The present findings need to be interpreted with caution, given the small number of 
subjects, the absence of neuropsychological tests to assess cognitive impairment and 
the lack of inflammatory data. Nor do we exclude the possibility that brain damage was 
caused by complications of thrombolytic therapy [49]. Nonetheless, the results do warrant 
further research to discern the interrelation of post-MI depression, MI-related brain dam-
age, inflammation and coronary heart disease.
In conclusion, our data are the first to show a release of S100B in serum during the first 
week after MI, and a positive correlation between serum S100B and depressive symptoms 
at 3- to 12-month follow-up. Although we do not entirely rule out the influence of cardiac 
S100B, several arguments favor cerebral damage as the main source of the serum-de-
rived S100B. The arguments include the positive correlation between S100B and depres-
sive symptoms at 3- to 12-month follow-up, the time course of the curve of S100B in the 
first week after MI and the absence of S100B elevation in 18% of the patients during the 
initial hospitalization for MI. The present data may imply that post-MI cerebral damage is 
associated with a subtype of post-MI depression.
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